完全植入式静脉通路装置首日使用对并发症有影响吗？
Is there any effect of first-day usage of a totally implantable venous access device on complications?
作者信息
Karanlik Hasan, Odabas Hatice, Yildirim Ilknur, Ozgur Ilker, Kilic Berkay, Sen Fatma, Kurul Sidika, Aydiner Adnan
机构信息
Surgical Oncology Unit, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey.
Division of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
出版信息
Int J Clin Oncol. 2015 Dec;20(6):1057-62. doi: 10.1007/s10147-015-0830-7. Epub 2015 Apr 25.
BACKGROUND
Our aim was to evaluate whether it is safe to use a totally implantable venous access device (TIVAD) on the day of implantation.
METHODS
We investigated data from 1315 cancer patients divided into two groups according to the time interval between TIVAD placement and the first use of the TIVAD to adminster chemotherapy: patients whose devices were used during the first 24 h after placement were enrolled into group 1 and patients whose devices were first used more than 24 h after device placement were enrolled into group 2.
RESULTS
Early complications were all related to device insertion and occurred before chemotherapy administration. Infection and venous thrombosis were the most frequent complications during the first 6 months after TIVAD insertion in both groups. However, the frequency of late complications was statistically the same for the two groups.
CONCLUSIONS
The early use of TIVADs appears safe. Usage of the catheter for chemotherapy administration during the first 24 h after insertion has no effect on the rate of complications.
背景
我们的目的是评估在植入当天使用全植入式静脉通路装置（TIVAD）是否安全。
方法
我们调查了1315例癌症患者的数据，根据TIVAD放置与首次使用TIVAD进行化疗之间的时间间隔将患者分为两组：在放置后24小时内使用装置的患者纳入第1组，在装置放置后超过24小时首次使用装置的患者纳入第2组。
结果
早期并发症均与装置插入有关，且发生在化疗给药之前。两组在TIVAD插入后的前6个月中，感染和静脉血栓形成是最常见的并发症。然而，两组晚期并发症的发生率在统计学上相同。
结论
早期使用TIVAD似乎是安全的。在插入后24小时内使用导管进行化疗给药对并发症发生率没有影响。
Zotero 插件